| Mark L Canny, OT | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Mark L Canny |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699740787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 102423 (Minnesota) | Primary |
| Provider Name | Mayo Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
The Associated Press reports: "President Barack Obama's advisers are urging critics of their health care overhaul to wait for Congress to finish writing legislation before issuing verdicts. They also signaled they are willing to wait longer than their White House-imposed August deadline for action if it means they can sway wary lawmakers.
Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.
Biomedical engineers at Case Western Reserve University are growing tracheas by coaxing cells to form three distinct tissue types after assembling them into a tube structure-;without relying on scaffolding strategies currently being investigated by other groups.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark L Canny, OT 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Mark L Canny, OT 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
The Associated Press reports: "President Barack Obama's advisers are urging critics of their health care overhaul to wait for Congress to finish writing legislation before issuing verdicts. They also signaled they are willing to wait longer than their White House-imposed August deadline for action if it means they can sway wary lawmakers.
Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.
Biomedical engineers at Case Western Reserve University are growing tracheas by coaxing cells to form three distinct tissue types after assembling them into a tube structure-;without relying on scaffolding strategies currently being investigated by other groups.
› Verified 2 days ago
Amy L Krekelberg, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Danielle Anshus, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Erika Hope Mckeever, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Deborah Engen, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Susan D Hansen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mary B Clark, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Sara Kathleen Tallman, O.T.D. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |